Drug Trial Radar · NCT04700124
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
808
Actual
Start
Apr 21, 2021
Primary completion
Oct 27, 2025
Study completion May 18, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Seagen Inc.; Astellas Pharma Inc
- First posted
- Jan 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \[gemcitabine plus cisplatin\] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).
Conditions
- Bladder Cancer
Interventions
PembrolizumabBiological
200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
Enfortumab vedotin (EV)Biological
1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
RC + PLNDProcedure
Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
GemcitabineDrug
1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
CisplatinDrug
70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free Survival (EFS)Time frame: Up to ~68 months
Locations
188 sites in 29 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix ( Site 0043)
Phoenix, Arizona
St Joseph Heritage Healthcare-Oncology ( Site 0035)
Fullerton, California
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0005)
Los Angeles, California
University of California San Francisco ( Site 0010)
San Francisco, California
Stanford University ( Site 0023)
Stanford, California
University of Colorado, Anschutz Cancer Pavilion ( Site 0009)
Aurora, Colorado
UF Health ( Site 0031)
Gainesville, Florida
Indiana University Melvin and Bren Simon Cancer Center ( Site 0050)
Indianapolis, Indiana
University of Iowa Hospital and Clinics ( Site 0029)
Iowa City, Iowa
University of Louisville, James Graham Brown Cancer Center ( Site 0022)
Louisville, Kentucky
Icahn School of Medicine at Mount Sinai ( Site 0011)
New York, New York
White Plains Hospital ( Site 0039)
White Plains, New York
Duke University Medical Center ( Site 0017)
Durham, North Carolina
Wake Forest Baptist Health ( Site 0014)
Winston-Salem, North Carolina
Oregon Health and Science University ( Site 0028)
Portland, Oregon
MidLantic Urology ( Site 0002)
Bala-Cynwyd, Pennsylvania
Saint Francis Cancer Center ( Site 0008)
Greenville, South Carolina
The University of Tennessee Medical Center ( Site 0034)
Knoxville, Tennessee
UT Southwestern Medical Center ( Site 0003)
Dallas, Texas
Houston Methodist Urology Associates ( Site 0033)
Houston, Texas
Urology of San Antonio ( Site 0020)
San Antonio, Texas
University of Wisconsin Hospital and Clinics ( Site 0037)
Madison, Wisconsin
Centro de Urología (CDU) ( Site 1552)
Buenos Aires, Argentina
Hospital Británico de Buenos Aires-Oncology ( Site 1551)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires ( Site 1554)
ABB, Buenos Aires F.D., Argentina
Asociación de Beneficencia Hospital Sirio Libanés ( Site 1553)
Buenos Aires, Buenos Aires F.D., Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1558)
Buenos Aires, Buenos Aires F.D., Argentina
Fundacion Estudios Clinicos-Oncology ( Site 1557)
Rosario, Santa Fe Province, Argentina
Macquarie University-MQ Health Clinical Trials Unit ( Site 1259)
Macquarie University, New South Wales, Australia
Mater Hospital Brisbane ( Site 1257)
South Brisbane, Queensland, Australia
Lyell McEwin Hospital ( Site 1252)
Elizabeth Vale, South Australia, Australia
Frankston Hospital-Oncology and Haematology ( Site 1258)
Frankston, Victoria, Australia
Complex Oncology Center Plovdiv ( Site 1151)
Plovdiv, Bulgaria
MHAT Central Onco Hospital OOD ( Site 1158)
Plovdiv, Bulgaria
MHAT Serdika ( Site 1152)
Sofia, Bulgaria
MHAT "Uni Hospital" OOD ( Site 1154)
Panagyurishte, Pazardzhik, Bulgaria
BC Cancer - Vancouver Center ( Site 0110)
Vancouver, British Columbia, Canada
CancerCare Manitoba ( Site 0108)
Winnipeg, Manitoba, Canada
Moncton Hospital ( Site 0107)
Moncton, New Brunswick, Canada
Ottawa Hospital Research Institute ( Site 0109)
Ottawa, Ontario, Canada
Showing 40 of 188 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.